NEX-I

NEX-I (Ticker: 493410 KS) develops cancer drugs by identifying factors that contribute to resistance to immuno-oncology treatments and targeting them with drug candidates. Its NEXORA platform identifies mechanisms and key factors behind resistance to immuno-oncology treatments and supports development of drugs targeting them. The pipeline has seven candidates, including NXI-101, licensed to Ono Pharmaceutical in 2024 and undergoing a Phase 1 trial in Japan, and NXI-201, in Phase 1/2 clinical development in South Korea and the United States.

The scheduled listing date on Korea Exchange (KOSDAQ) is November 12, 2026. The offering comprises 5,000,000 shares at a confirmed price of KRW 8000 per share, compared with an indicative range of KRW 10500–13000. At the confirmed offer price, the total offering size is KRW 40.00 billion, approximately $30.01 million, excluding any unexercised over-allotment.